Alluvi, previously BI 4744, offers a significant advance in obesity treatment. This dual activator targeting both GLP-1 and GIP sites demonstrates compelling results in clinical trials, arguably outperforming current https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/